Showing 2351-2360 of 8819 results for "".
Therapeutic Approaches in Pediatric Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37158/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, explains how to adjust a therapeutic approach to pediatric atopic dermatitis, particularly when considering long-term use of topical steroids or calcinPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 6
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-6/32904/In the final installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, recap the recommended protocol for treating generalized psoriasis treatment, starting from the initial diagnosis, as well as the safety of targetedExpanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.What Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinDERM2020 Exhibitor Reaction: Brett Fair, EPI Health
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-brett-fair-epi-health/19847/Brett Fair of EPI Health, a DERM2020 exhibitor, tells us what he thinks of the new virtual meeting world and how DEF is dominating it for dermatology!Insights on Care for Skin of Color, Part 2
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-2/18185/Hilary Baldwin, MD and James Q. Del Rosso, DO continue their discussion with host Neal Bhatia, MD about managing skin of color. They address long-term management strategies and the need for cultural awareness.Updates in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/updates-in-pediatric-dermatology/19733/2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis Bioteherapu